Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

• ClinicalTrials.gov Identifier: NCT02241551
• Recruitment Status: Terminated
• First Posted: September 16, 2014
• Results First Posted: June 15, 2018
• Last Update Posted: July 26, 2018
• Sponsor: Nathan Bahary, MD
• Information provided by (Responsible Party): Nathan Bahary, MD, University of Pittsburgh

Study Description

Brief Summary:

This is a prospective, randomized phase II trial. Patients diagnosed with borderline resectable pancreatic adenocarcinoma will be randomly assigned to one of two treatment arms, either mFOLFIRINOX or gemcitabine and nab-paclitaxel. After three cycles of treatment in the gemcitabine/nab-paclitaxel arm and 6 cycles in the mFOLFIRINOX arm, patients will be restaged with CT scans and if they remain borderline resectable or have improvement of their disease They will then proceed to SBRT followed by surgical resection.

Condition or disease	Intervention/treatment	Phase
Borderline Resectable Pancreatic Cancer	Drug: gemcitabine/nab-paclitaxel; Drug: mFOLFIRINOX	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 2 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Study of Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
• Study Start Date: December 2014
• Actual Primary Completion Date: March 3, 2017
• Actual Study Completion Date: March 3, 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: gemcitabine/nab-paclitaxel; three cycles of treatment in the gemcitabine/nab-paclitaxel	Drug: gemcitabine/nab-paclitaxel; three cycles of treatment in the gemcitabine/nab-paclitaxel; Other Names: Gemzar; ABRAXANE
Experimental: mFOLFIRINOX; 6 cycles in the mFOLFIRINOX	Drug: mFOLFIRINOX; 6 cycles in the mFOLFIRINOX; Other Names: irinotecan; fluorouracil; oxaliplatin

Outcome Measures

Primary Outcome Measures :

1. Safety and Efficacy Using Neo-adjuvant Gemcitabine Plus Nab-paclitaxel in Patients Receiving SBRT and Surgery for Borderline Resectable Pancreatic Cancer, Using Neo-adjuvant mFOLFIRINOX as a Control [ Time Frame: up to 5 years ]
   Efficacy: pathological complete response (pCR) and R0 resection. Safety: Grade 4 toxicity.

Secondary Outcome Measures :

1. R0 Resection Rates in Borderline Resectable Pancreatic Cancer [ Time Frame: Up to 5 years ]
2. Incidence of Grade 3 and 4 Toxicities for the 2 Chemotherapy Regimens That Occur After Cycle 1 Day 1 [ Time Frame: Up to 5 years ]
   According to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTAE, v4.0)
3. Ca19-9 Response to Neoadjuvant Chemotherapy [ Time Frame: Up to 5 years ]
4. Time to Disease Progression [ Time Frame: Up to 5 years ]
5. Measurement of Biomarkers (SPARC, RM1 and SMAD4) in Tissues [ Time Frame: Up to 5 years ]
   This wil be measured in tissues that are obtained at screening and in the resected tumour specimen
6. Radiological Response Rate to Therapy [ Time Frame: Up to 5 years ]
   Radiological improvements will be evaluated by determining changes in density of measurable disease on CT scan pre and post chemotherapy
7. Quality of Life Effects of Chemotherapy on Patients Receiving Chemotherapy and SBRT [ Time Frame: Up to 5 years ]
   This will be measured using the FACT-HB questionaire

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

All patients must meet the following criteria within 28 days of randomization (unless otherwise indicated) to be enrolled in the protocol:

• Histologically or cytologically proven adenocarcinoma of the pancreas. If the patient has mixed tumor with predominant adenocarcinoma pathology, they can be enrolled.
• Subjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0 being eligible; and have a primary tumor of the pancreas (either pancreatic head, neck, uncinate process, or body/tail)
• The tumor must be deemed as being borderline resectable. Final CT confirmation of surgical staging/ eligibility will be at the discretion of the pancreatic surgeon of the patient.
• Disease is confined to locoregional site as confirmed by the CT and / or diagnostic staging laparoscopy to avoid occult peritoneal deposits. Diagnostic laproscopy will be only if absolutely required
• Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) on imaging studies CT
• Screening Endoscopic ultrasound if done prior to consent but within 6 weeks of expected randomization date it may be used.
• Karnofsky performance status greater than or equal to 70 or Eastern Cooperative Oncology Group (ECOG) performance of 0-2.
• Age > 18
• Estimated life expectance > 12 weeks
• If female patient is of child bearing potential, she must have a negative serum pregnancy test (βhCG) documented up to 72hrs prior to administration of first study drug
• Patient has screening blood work performed which includes the following (should be drawn ≤ 14 days prior to randomization)
• absolute neutrophil count (ANC) > 1.5 x 109/L
• Platelet count ≥ 100000/mm3
• Hemoglobin (HgB) ≥ 9g/dL
• aspartate aminotransferase (AST),Alanine Aminotransferase (ALT)≤ 2.5 x upper limit of normal (ULN) Total Bilirubin ≤ ULN
• Serum Cr within normal limits (WNL)
• Coagulation studies with Prothrombin Time and International Normalized Ratio (PT/INR) and partial thromboplastin time (PTT) within normal limits (±15%). • Patient has a urinalysis obtained (≤14 days prior to randomization) and the results are deemed not clinically significant by the investigator.
• Patient has no evidence of jaundice at the time of enrolment. If stent is required to alleviate jaundice, it should be metallic. If patient has a previously placed stent and this is plastic, this should be changed to metallic.
• Patient's pain symptoms have remained stable with no adjustment to analgesics within 7 days prior to randomization. Patient must be able to swallow entreat medications with no requirement for a feeding tube. Patient's must not have intractable nausea or vomiting which prohibits the patient from oral medications
• Diabetes must be controlled prior to enrollment
• Disease must be encompassed in a reasonable SBRT "portal" as defined by the treating radiation oncologist

Exclusion Criteria:

• Ineligible Histology including non-adenocarcinomas, adenosquamous carcinoma, islet cell carcinomas, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct and ampullary carcinomas
• Evidence of distant metastasis on upright chest x-ray, CT or other staging studies
• Subjects with recurrent disease
• Prior radiation therapy to the upper abdomen or liver at the discretion of the treating radiation oncologist could impair delivery of the prescribed radiation treatment
• Prior chemotherapy
• Subjects in their reproductive age who are breast feeding or have a positive pregnancy test
• Any co-morbid condition of sufficient severity to limit full compliance with the protocol per assessment by the individual treating physician
• Concurrent active infection
• Previous or current malignancies of other histologies within the last 3 yrs prior to randomization; with the exception of cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer
• Patient with known historical or active infection with HIV, Hepatitis B or Hepatitis C
• Patient who has undergone recent major surgery, other than diagnostic surgical procedure within 4 weeks prior to randomization.
• Patient who has a history of allergy or hypersensitivity to any of the study drugs.
• Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, interstitial pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
• Patients with greater than 2 screening peripheral neuropathy.

Contacts and Locations

Locations

United States, Pennsylvania

Hillman Cancer Center

Pittsburgh, Pennsylvania, United States, 15232

Sponsors and Collaborators

Nathan Bahary, MD

  Study Documents (Full-Text)

Documents provided by Nathan Bahary, MD, University of Pittsburgh:

Study Protocol and Statistical Analysis Plan  [PDF] April 27, 2015

More Information

• Responsible Party: Nathan Bahary, MD, Associate Professor, University of Pittsburgh
• ClinicalTrials.gov Identifier: NCT02241551
• Other Study ID Numbers: UPCI 13-143
• First Posted: September 16, 2014
• Results First Posted: June 15, 2018
• Last Update Posted: July 26, 2018
• Last Verified: June 2018

Keywords provided by Nathan Bahary, MD, University of Pittsburgh:

Borderline; Resectable; Pancreatic; Cancer; Neoadjuvant; Chemotheraphy; Gemcitabine; Nab-Paclitaxel; mFOFIRINOX; Sterotatic Body Radiation Therapy

Additional relevant MeSH terms:

Pancreatic Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases; Gemcitabine; Paclitaxel; Fluorouracil; Oxaliplatin; Irinotecan; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Antiviral Agents; Anti-Infective Agents; Enzyme Inhibitors; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Topoisomerase I Inhibitors; Topoisomerase Inhibitors